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Abstract: 
The aim of this study was to identify predictor sets of genes whose over- or under-expression in 
human sporadic adrenocortical tumors would help to identify malignant versus benign tumors 
and to predict post-surgical metastatic recurrence. For this, we analyzed the expression of 230 
candidate genes using cDNA microarrays in a series of 57 well characterized human sporadic 
adrenocortical tumors (33 adenomas and 24 carcinomas). We identified two clusters of genes 
(the IGF2 cluster containing 8 genes including IGF2, and the Steroidogenesis cluster 
containing 6 genes encoding steroidogenic enzymes plus 8 other genes) whose combined levels 
of expression appeared as good predictors of malignancy. This predictive value was as strong as 
that of the pathological score of Weiss. The analysis of the population of carcinomas (13 tumors) 
for genes whose expression would be strongly different between recurring and non-recurring 
tumors allowed the identification of 14 genes meeting these criteria. Among these genes, there 
are probably new markers of tumor evolution that will deserve further validation on a larger 
scale. Taken together, these results show that the parallel analysis of the expression levels of a 
selected group of genes on microgram quantities of tumor RNA (a quantity that can be obtained 
from fine-needle aspirations) appears as a complementary method to histopathology for the 
diagnosis and the prognosis of evolution of adrenocortical carcinomas.   
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Introduction:  
Although adrenocortical tumors are highly prevalent in the human population (3 to 7% at 
autopsy and/or in radiological series), only a small proportion cause endocrine disorders and 
less than 5% are malignant (1, 2). Many of the tumors that do not secrete aberrant levels of 
steroids are now discovered as incidentalomas (3). The most frequent clinical presentations of 
adrenocortical adenomas and carcinomas are Cushing’s syndrome (hypersecretion of 
glucocorticoids) with or without associated androgen secretion and virilism, and Conn’s 
syndrome caused by small adenomas (less than 20 mm in size) exclusively secreting 
aldosterone. Estrogen-producing tumors are rare and usually malignant. About 50% of 
adrenocortical carcinomas secrete steroid precursors with reduced bioactivity. On average, 
adrenocortical carcinomas are diagnosed rather late at a stage when the tumor has often already 
spread occult or detectable metastases. The prognosis of adrenocortical carcinomas is therefore 
very poor with a mean patient survival rate of 20% at 5 years (4).  
Despite some recent progress, the understanding of the biology of adrenocortical tumors is still 
partial. Clonal composition analyses and comparative genomic hybridization experiments have 
established that adrenocortical tumorigenesis is a multistep process resulting from sequential 
genetic alterations leading to progression from normal to adenomatous and, eventually, to 
malignant phenotypes (5-8). Several studies have demonstrated an increased frequency of DNA 
copy number changes in large malignant tumors that are infrequent in small benign lesions. The 
most common modification, observed in 85% of carcinomas, is the overexpression of the 
insulin-like growth factor II (IGF2) gene, that is associated with paternal isodisomy at the 
11p15 locus (9, 10). However, the high number of chromosomal alterations and dysregulations 
of gene expression that are observed suggests that each tumor is potentially distinct from all 
others at the molecular and clinical levels (8, 9, 11, 12). Prognosis is thus not likely to be 
associated with abnormal expression of a single gene but rather with the combined disturbances 
of several genes. Massively parallel molecular analyses should then be developed in order to 
identify such combinations of misexpressed genes. The recently developed cDNA array 
technology, which allows the simultaneous analysis of mRNA expression levels of hundreds of 
genes, may be the method of choice. Several recent studies have demonstrated that the 
determination of gene expression signatures among clinically and histologically homogeneous 
groups of tumors permits the identification of subgroups with different evolution prognosis 
(13-18). 
The classification of adrenocortical tumors between adenomas and carcinomas relies on several 
criteria including the size of the resected tumor mass, the degree of invasiveness and the 
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histopathological examination. Tumors presenting with local or regional invasion and/or 
metastases (McFarlane stages III and IV) are unequivocally classified as malignant. Conversely, 
in the case of purely localized tumors, the diagnosis is based on histopathological examination 
using the criteria defined by Weiss (19, 20). However, in ~30% of these tumors (1≤ Weiss score 
≤3), histopathology is unable to provide an unambiguous answer. There is therefore a crucial 
need for additional reliable analyses that could help the clinician in diagnostic and subsequent 
therapeutic decisions. In a recent retrospective study on a large cohort of patients with sporadic 
adrenocortical tumors, the analysis of 3 molecular alterations (loss of heterozygosity at the 
17p13 locus, uniparental disomy at the 11p15 locus and overexpression of the IGF2 gene) 
revealed that they were independent predictors of shorter disease-free survival in univariate 
analysis (9). In a multivariate analysis, histological grade (relative risk, 4.2) and 17p13 LOH 
(relative risk, 21.5) appeared to be independently associated with recurrence (9).  
The aim of this study was to take advantage of the cDNA array technology to identify predictor 
sets of genes whose over- or under-expression in adrenocortical tumors would help, on one 
hand, to discriminate between benign and malignant tumors, and, on the other hand, to identify 
the subgroup of patients bearing carcinomas at high risk of recurrence, in whom adjuvant 
therapy may be applied.  For this purpose, using cDNA microarrays, we analyzed the 
expression of 230 candidate genes in a series of 57 sporadic adrenocortical tumors from adult 
patients who had been carefully followed up by five medical centers within the French clinical 
network COMETE (COrtico & MEdullo-surrénales Tumeurs Endocrines). We identified two 
clusters of genes whose levels of expression appeared as good predictors of malignancy. Their 
combination improved their predictive value to a level similar to but not better than the 
pathological score of Weiss. In addition, we identified a set of 14 genes (including ITGB2, 
GZMA, and ATF1) that allowed to significantly predict metastatic recurrence among the 13 
carcinomas included in the analysis. 
 
 
Materials and Methods: 
Tumor samples and RNA extraction: 
Samples of primary sporadic adrenocortical tumors were obtained from 57 adult patients (14 
men, 43 women) referred to and followed by the Endocrine Departments of Cochin, Georges 
Pompidou, Gustave Roussy, Armand-Trousseau and Albert Michallon Hospitals (Paris, 
Villejuif and Grenoble, France). We excluded cases with Conn adenomas, i.e. with tumors of 
20 mm or less with a pure aldosterone hypersecretion. Written informed consent for germ-line 
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and somatic DNA analysis was obtained from each patient and the study was formally 
approved by an institutional review board (CCPPRB Paris-Cochin, July 1996). Access to the 
collected information was obtained from all of the patients in accordance with national ethic 
rules. The median age of the patients at the time of diagnosis was 41 years (range 18-79). After 
surgical resection, tumors were dissected : a fragment was processed for paraffin inclusion and 
further histopathological examination whereas adjacent pieces were immediately frozen in 
liquid nitrogen and stored either in liquid nitrogen or at –80 C until RNA extraction and further 
molecular analysis. Tumors were classified according to Weiss criteria : for each tumor, a 
Weiss score between 0 and 9 was determined according to the presence or absence of nine 
predefined histological features (19, 20). The group of tumors analyzed in this study included 
33 adenomas (Weiss score ≤3) and 24 carcinomas (Weiss score≥4). The major characteristics 
of the patients included in this study and of their tumors are summarized in Table I.  
Total RNA was extracted as previously described (21) and purified by ultracentrifugation 
through a cesium chloride gradient. The integrity of RNA was confirmed on ethidium 
bromide-stained gels.  
 
Quantitative RT-PCR: 
2 µg of total RNA were reverse-transcribed for 30 min at 37C with SuperScript II RnaseH 
reverse transcriptase (Invitrogen, Cergy Pontoise, France) under conditions recommended by 
the manufacturer. Aliquots (1/25 of the RT reaction volume) were subjected to quantitative real 
time PCR on a Light CyclerTM apparatus (Roche Diagnostics, Meylan, France). The PCR 
reactions were performed using the following primers : (GCATCGTTGAGGAGTGCTGTTTC 
and GGGGTATCTGGGGAAGTTGTCC) for IGF2, (TCCACCCACCTGGCTTCAT and 
GCAGGACCTGGGCTTGTG) for HSD3B1, (GGCAAATGCTTTCGCCTCTGGGTC and 
TTGTTGGTTTTCGGAACTGAGC) for 18S ribosomal RNA and SYBR green PCR core 
reagents (LightCycler-FastStart Master SYBR Green I, Roche Diagnostics) according to the 
manufacturer’s instructions. PCR conditions were: step 1: 95 C for 10 min; step 2: 40 cycles 
consisting of 95 C for 15 s, 57C for 6s (IGF2) or 59C for 5s (HSD3B1 and 18S), and, 72 C for 
12 s (IGF2) or for 10s (HSD3B1 and 18S). The samples were analyzed in duplicate and the 
results were normalized to 18S expression levels. 
 
Preparation of cDNA microarrays: 
Gene expression was analyzed by hybridization of arrays with radiolabeled probes. The arrays 
contained PCR amplification products of 230 human cDNA clones obtained from the IMAGE 
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consortium through either the RZPD (Berlin, Germany) or the Human Genome Mapping 
Project Resource Center (Hinxton, UK). These included 187 “cancer-related“ genes (including 
genes encoding cell cycle control proteins, growth factors, growth factor receptors, 
transcription factors, cell adhesion molecules, proteins involved in cell invasion, angiogenesis 
and chemoresistance), 34 “adrenal cortex-specific“ genes (including genes encoding hormone 
receptors, components of the cAMP signalling pathway, steroidogenic enzymes and 
components of the IGF2 system) and 9 control genes. Their identity was verified by restriction 
mapping and/or 5’tag-sequencing of plasmid DNA. The use of control clones, PCR 
amplification and robotical spotting onto Nytran-N+ membranes (Schleicher & Schuell, 
Ecquevilly, France) were performed as described in (22). The list of spotted genes is available 
upon request. 
 
Data analysis and statistical methods: 
Hybridization signals (mean values of duplicate spots) were recorded and quantified with a 
ß-imager (Fuji BAS 5000). The values were then corrected with Image Gauge software for the 
amount of spotted DNA and the variability of experimental conditions, normalized as a ratio to 
the total amount of membrane-bound radioactivity, log-transformed and displayed as relative 
values median-centered in each row and column (14, 22). Average-linkage hierarchical 
clustering was then applied to determine the closest proximity between tumor samples and 
between gene expression levels using the Cluster program (with Pearson correlation as 
similarity metric) and the results were displayed using the TreeView program (23). Genes 
distinguishing clinical parameters (adenoma vs carcinoma; recurrences) were searched using 
Student T-test. 
Survival analysis was performed using the Kaplan-Meier method (24) and compared between 
groups using the log rank test (univariate analysis). The calculations were performed using 
StatView software. 
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Results: 
 
Gene expression profiling of human adrenocortical tumors: 
The mRNAs from 57 human adrenocortical tumor samples were hybridized with cDNA arrays 
carrying the 230 selected genes. The overall expression patterns of these 57 tumors were 
analyzed with hierarchical clustering and displayed in a color-coded matrix (Figure 1A). Tumor 
samples are classified on the horizontal axis and genes on the vertical axis and both are ordered 
on the basis of similarity of their expression profiles. Overall similarity of gene expression 
profiles is shown as a dendrogram where branch length is inversely correlated with similarity. 
As shown in Figure 1B, the two groups of tumors separated on the basis of the expression 
profiles of all genes contained clearly distinct percentages of adenomas (green squares) versus 
carcinomas (red squares). Supervised analysis allowed to highlight 2 clusters of genes 
associated with the adenoma/carcinoma distinction (Figure 1 red curve). They are indicated by 
colored lines on the dendrogram at left of Figure 1. Statistical analysis of the expression of each 
gene belonging to these two clusters revealed that they were significantly distinct between 
adenomas and carcinomas (Figure 1A, right panel). The identity of the genes from each cluster 
is presented in Table 2. The “IGF2” cluster contains 8 genes which encode growth factors 
(IGF2, TGFB2), growth factor receptors (FGFR1, FGFR4, MST1R, and TGFBR1) as well as 
KCNQ1OT1 (also known as LIT1, ie long QT internal transcript1) and GAPD, a presupposed 
housekeeping gene. The “steroidogenesis cluster” contains 14 genes. Six of them encode 
proteins directly involved in the steroid biosynthesis pathway : StAR (steroidogenic acute 
regulatory protein), CYP11A (Cholesterol side chain cleavage enzyme), HSD3B1 
(3ß-hydroxysteroid dehydrogenase/∆5-4 isomerase type I), CYP11B1 (steroid 
11ß-hydroxylase), CYP21A2 (steroid 21-hydroxylase), CYP17 (steroid 17α-hydroxylase). It 
also contains PPM1A (protein phosphatase 1A), S100B (S100 calcium-binding protein, ß 
chain), GPC3 (glypican 3), INHA (inhibin α chain), CREM (cAMP response element 
modulator), RB1 (Retinoblastoma 1), NME1 (Non-metastatic protein 23, NM23) and TGFBR3 
(transforming growth factor ß type III receptor).  
We then clusterized again the tumors as a function of the expression profiles of each individual 
gene cluster (Figure 2). The level of expression of the IGF2 cluster allowed to separate a 
subpopulation (low expression) among which 90% of the tumors were adenomas, from another 
(high expression) among which 75% were carcinomas. On the opposite, considering the 
steroidogenesis cluster, low level of expression correlated with carcinomas (81% in the 
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low-expressing group) whereas high level of expression correlated with adenomas (93% in the 
high-expressing group). 
In order to confirm these results by another quantitative method, we analyzed the mRNA 
expression level of one representative gene from each cluster, namely IGF2 and HSD3B1, by 
real-time quantitative RT-PCR. The results shown in Figure 3 indicated a good correlation 
between both methods.  
 
Disease-free survival analysis of the whole tumor population : 
Out of the 57 patients whose tumor RNAs were analyzed on DNA microarrays, 8 had 
incomplete surgery and 9 had unsufficient follow-up. We could however include 40 patients in 
a retrospective study of recurrence-free survival. In this group, the median duration of 
follow-up was 33 months (range 4-97). For patients without recurrence, the minimal follow-up 
period was 12 months. The Kaplan-Meier estimate of disease-free survival was 82.5% at 2  
years (Figure 4A). During the follow-up period, 4 patients died of metastatic recurrence. Seven 
patients (17.5%) underwent recurrence 2-10.5 months after initial surgery (median= 6.7 
months). 
Univariate analyses were performed using the Kaplan-Maier statistical method. We first 
analyzed recurrence-free survival as a function of the expression profile of each individual gene 
cluster. The results of Figure 2 were used to classify each individual tumor into two groups 
characterized by low or high expression of the considered cluster. The curves shown in Figure 4 
clearly indicate that the IGF2 (p< 0.01) and Steroidogenesis (p< 0.01) clusters were significant 
predictors of malignancy. They were not as good predictors however as the pathological grade 
(Weiss score, Figure 4E) as the rate of recurrence among the group of tumors presenting a 
Weiss score ≥4 was 54% whereas it was only about 40% among the groups that presented either 
a high level of expression of the IGF2 gene cluster or a low expression level of the 
Steroidogenesis cluster. However, the combination of these two latter gene clusters allowed the 
identification of a subpopulation of tumors with low expression of the Steroidogenesis cluster 
and high expression of the IGF2 cluster that presented the same risk of post-surgical recurrence 
as the group of tumors with a Weiss score ≥4 (Figures 4E and 4F). This observation is the first 
demonstration for adrenocortical tumors that the analysis of the pattern of expression of a 
limited number of genes (22 genes in total) is as predictive as the pathological grading.  
 
Analysis of the steroid secretion profiles: 
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Another question that can be adressed in this study is the relationship between the steroid 
secretion profiles and the genetic expression profiles of these tumors. Among the tumor 
population studied, 23 overproduced glucocorticoids, 2 overproduced mineralocorticoids, 17 
had a mixed secretion profile and 8 were non-secreting. Three tumors overproduced androgens 
and 2 overproduced estrogens. As shown in Figure 5, most glucocorticoid-secreting tumors (19 
out of 23, 82%) presented a high level of expression of the Steroidogenesis cluster. 
Unexpectedly however, most (16 out of 19; 84%) of these differentiated tumors presented a low 
level of expression of the IGF2 cluster. On the other hand, most tumors with a mixed steroid 
production profile and most non-secreting tumors preferentially expressed the IGF2 cluster at a 
high level and the steroidogenesis cluster at a low level. This may reflect the known observation 
that glucorticoid overproduction is observed more frequently in adenomas than in carcinomas 
(2, 4).  
 
Disease-free survival analysis of adrenocortical carcinomas : 
We then separately analyzed the group of carcinomas (Weiss score ≥4) and asked whether we 
could identify a gene cluster whose expression level could allow to discriminate between 
recurring and non-recurring tumors. Unfortunately, only 13 of these 24 carcinomas could be 
included in a retrospective study of recurrence-free survival as tumors that were already 
metastatic before surgery had to be excluded from the analysis. Supervised analysis using a 
Student T test at 3% risk lead to the identification of 14 genes whose expression levels were 
clearly distinct between recurring and non-recurring tumors (Table 3; Figure 6A). These genes 
were not associated to any particular cluster (Figure 1A, blue curve), probably because of the 
small number of samples. As shown in Figure 6B, the group of recurring carcinomas could be 
perfectly separated from the group of non-recurring tumors on the basis of overexpression (6 
genes) or underexpression (8 genes) of these genes. 
 
Discussion: 
An increasing number of studies have suggested the usefulness of cDNA array-based gene 
expression profile determination for cancer classification and some of them have succeeded in 
bringing up novel prognostic information (13-18). Using this technology, we profiled a series 
of 57 human sporadic adrenocortical tumors using a set of candidate genes, the majority of 
which are implicated in oncogenesis or steroidogenesis. For 40 of these tumors, the follow-up 
and clinical information was sufficient to perform a retrospective study. We aimed at 
identifying groups of genes whose expression level would help, on one hand, to discriminate 
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between benign and malignant tumors, and, on the other hand, to identify the subpopulation of 
carcinomas that are more likely to recur.  
Two independent clusters of genes (the IGF2 and Steroidogenesis clusters) were independently 
found to significantly discriminate between two populations of tumors with distinct clinical 
outcome. Their combination allowed to identify a subpopulation of tumors with both high 
expression level of the IGF2 cluster and low expression of the Steroidogenesis cluster that have 
a higher probability of metastatic recurrence over a period of 24 months (60% of this group of 
tumors recurred). The analysis of the expression level of this group of 22 genes appeared almost 
as powerful as the well recognized histological score of Weiss at identifying the true 
carcinomas. Although it may appear disappointing that such a sophisticated genetic analysis 
using cDNA microarrays does not overperform the routinely used histopathological method in 
terms of prediction power, one should acknowledge that the possibility to miniaturize this 
technique opens new fields for the diagnostic analysis of adrenocortical tumors. We show here 
that the analysis of the expression level of a group of 22 genes is sufficient to predict metastatic 
recurrence with the same index of confidence as the histological score of Weiss. Since 1 µg of 
total tumor RNA is certainly sufficient to carry out this genetic analysis (2 µg of RNA were 
used in the present study), these results open the way to the molecular diagnostic performed 
before the surgery on a needle biopsy of the tumor. As recently reviewed, fine-needle 
aspirations appear as a sensitive and accurate method to collect biological material for the 
diagnosis of adrenocortical masses (25).  
 
The identity of the genes that cosegregate with IGF2 in the so-called IGF2 cluster is extremely 
interesting. Two genes encode fibroblast growth factor receptors of the FGF family : FGFR1 
and FGFR4. The fibroblast growth factors FGF-1 and FGF-2 are expressed in the adrenal 
cortex. They are the most powerful mitogens for adult steroidogenic adrenocortical cells (26) as 
well as for the human adrenocortical tumor cell line NCI-H295R (27). They are also known to 
stimulate the proliferation of endothelial and mesenchymal cells. They bind to a family of four 
tyrosine kinase receptors, among which FGFR1 and FGFR4 are the most strongly expressed in 
the adrenal cortex (28, 29). The overexpression of these two FGF receptors in adrenocortical 
cancers is thus likely to participate in their increased proliferation and vascularization. Then, 
FGF receptors potentially represent new targets for novel therapeutic approaches of 
adrenocortical carcinoma, a type of cancer that turns out to be resistant to conventional 
antimitotic agents (30). Two genes encode TGFß2, a member of the TGFß superfamily and its 
signalling serine/threonine kinase receptor TGFß-R1. TGFß1 is an autocrine factor produced 
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by the adrenal cortex (31, 32). It has no effect on the proliferation of steroidogenic cells but it 
strongly inhibits their steroidogenic activities through down-regulation of StAR and CYP17 
expression (33, 34). Although TGFß2 has been less characterized in this tissue, it is known to 
share the same type 1 and type 2 receptors as TGFß1, to signal through the phosphorylation of 
the same Smad proteins (Smad2 and Smad3) and to have similar inhibitory effects on 
adrenocortical steroidogenesis (our unpublished observations). It is tempting to speculate that 
the overexpression of TGFß2 and its type 1 receptor in adrenocortical carcinomas may 
participate in the dedifferentiation of these tumors. Indeed, in our study, 6 out of 8 
non-secreting tumors presented with a high level of expression of the IGF2 cluster (Figure 6). 
Two previous studies have analyzed TGFß1 expression in adrenocortical tumors and have 
characterized a decreased expression of both the protein and the mRNA in carcinomas as 
compared to normal tissue and adenomas (35, 36). In our study, both TGFß1 and TGFß2 cDNA 
probes were present on the arrays, but only TGFß2 appeared to cosegregate with other genes 
and to be overexpressed in carcinomas. Complementary experiments are required to establish 
whether there is a shift in expression from TGFß1 toward TGFß2 during adrenocortical tumor 
progression. One gene (MST1R) encodes Ron, a tyrosine kinase receptor for macrophage 
stimulating protein-1 that has been reported to be expressed in the adrenal glands, both at the 
embryonic and the adult stages (37). In adrenomedullary PC12 cells, macrophage stimulating 
protein 1 has been shown to be a potent mitogen. It is difficult however to speculate about its 
possible effect in adrenocortical tumors until some experiments are carried out in this cell 
system. Another gene of this cluster is KCNQ1OT1, which belongs to the same 11p15.5 region 
as the IGF2 gene. KCNQ1OT1 encodes a non-coding antisense transcript within intron 10 of 
the KCNQ1 gene and might be involved in the regulation of parental imprinting of the 
centromeric domain of the 11p15 region. The KCNQ1OT1 and the IGF2 genes are the only 
known genes in the 11p15 region that are maternally-imprinted and paternally-expressed. We 
previously showed that the main mechanism for overexpression of the IGF2 gene in malignant 
adrenocortical tumors was a paternal isodisomy (loss of the maternal allele and duplication of 
the paternal allele) (10, 21). It is therefore not surprising to find the concomittant expression of 
these two genes in the IGF2 cluster. The last gene belonging to this cluster is GAPD, encoding 
glyceraldehyde-3-phosphate dehydrogenase, a presupposed housekeeping gene. It has been 
reported previously that GAPD is up-regulated under a variety of circumstances including 
hypoxia and apoptosis (38, 39), two events that are likely to occur in the center of solid tumors. 
It is therefore not so unexpected to find this gene overexpressed in the population of 
adrenocortical carcinomas. It should be noted that this overexpression could not result from a 
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technological artefact since GAPD overexpression would be unlikely to non-randomly occur in 
one particular subpopulation of tumors. 
 
Out of the 14 genes present in the Steroidogenesis cluster, 6 encode enzymes or proteins 
directly involved the steroid biosynthesis pathway: the mitochondrial protein StAR, that 
facilitates the tranfer of cholesterol to the inner mitochondrial membrane, the cytochromes 
P450scc (cholesterol desmolase), P450c17 (17α-hydroxylase), P450c21 (21-hydroxylase), 
P450c11B1 (11ß-hydroxylase) and 3ß-hydroxysteroid dehydrogenase-isomerase. However, 
the correlation between the level of expression of these different enzymes in each individual 
tumor and their steroid secretion profile is not trivial. This indicates that the level of expression 
of some regulatory proteins, acting at the post-transcriptional level to modulate protein 
expression and/or enzymatic activity, has to be taken into consideration to fully explain the 
steroidogenic profiles of the tumors.  
 
Another original observation in this study is the identification of a group of 14 genes whose 
expression level allowed to perfectly discriminate recurring from non-recurring tumors among 
the 13 carcinomas analyzed. Among these genes is ITGB2, encoding integrin ß2, a common 
subunit for several receptors specifically expressed at the surface of leukocytes (40). Integrin ß2 
associates with distinct  subunits to form αLß2, αMß2, αDß2 or αXß2 integrins.  These 
integrins are receptors for ICAM1-4 and fibrinogen. Integrin αLß2 (LFA-1) plays an important 
role in the rolling of leukocytes at the surface of the endothelium and their extravasation, as a 
receptor for ICAM-1 and ICAM-2 (41). This increased expression of ITGB2 is therefore likely 
to reflect an increased tumor infiltration by leukocytes. Granzyme A, which is encoded by a 
gene belonging to this same cluster, is a trypsin-like serine protease that is secretd by T 
lymphocytes and participates in target cell lysis during cell-mediated immune response (42, 43). 
Expression of GZMA, like that of ITGB2, is thus likely to reflect infiltration by immune cells. 
The inflammatory status of the carcinoma at time of resection could thus represent an important 
parameter to take in consideration for the prediction of metastatic evolution. The third gene in 
this cluster that is expressed with markedly distinct intensities between recurring and 
non-recurring carcinomas is ATF1. This gene encodes a cAMP-dependent transcription factor 
of the CREB family that is ubiquitously expressed. It was recently shown to be expressed in the 
human tumor cell line NCI-H295R where, together with CREMτ, it functionally compensates 
for the lack of CREB (44).  
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In conclusion, this is the first study reporting the parallel analysis of the expression profiles of 
hundreds of genes in human sporadic adrenocortical tumors in correlation with the clinical 
follow-up of the cancer patients. The deliberate selection of a limited number of known genes 
with established biological functions (230 in this study) prevents us from extrapolating too 
much about the etiology of the disease. Certainly, a pangenomic analysis may be more 
successful in identifying new genes associated with adrenocortical tumorigenicity. During the 
course of the preparation of this manuscript, two such studies appeared in the literature (45, 46). 
Giordano et al. analyzed the expression of 10,500 unique genes in a series of 11 adrenocortical 
carcinomas and 4 adenomas and compared these expression profiles with that of normal adrenal 
cortex tissue (45). However, no prognostic analysis based on clinical follow-up was carried out 
in this extensive work. Interestingly, several of the most differentially expressed genes 
identified in this large scale study were also found in our clusters, including IGF2, FGFR1 and 
CYP11B1. In the most recent study, Bourdeau et al. analyzed the expression of a similar 
number of genes in a series of 8 ACTH-independent macronodular adrenal hyperplasia and 
identified candidate genes up- and down-regulated in this rare disorder (46). The approach that 
we used has proven successful in identifying a set of 22 predictor genes  which are altogether 
reasonably good indicators of malignancy. It has also identified a cluster of 14 genes that seems 
to have a prognostic interest to identify the subpopulation of carcinomas that are at risk of 
post-surgical recurrence. Given the small size of this latter group of carcinomas analyzed, these 
results will deserve further validation on a larger population and through the use of 
complementary techniques such as in situ hybridization or immunohistochemistry. 
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Legends to the Figures: 
 
Figure 1: Expression patterns of 230 genes in 57 human sporadic adrenocortical tumors.  
A- Each row represents a single gene and each column represents a single tumor sample. 
Genes are referenced by their HUGO abbreviation as used in Locus Link 
(http://www.ncbi.nlm.nih.gov/LocusLink/). The results are shown as relative 
expression levels (relative to the median value of each row and each column) and are 
represented with a color scale indicated at the bottom ranging from 1/100 to 100-fold 
changes. Red and green indicate expression levels respectively above and below the 
median. The clustering program arranges samples along both vertical and horizontal 
axis so that the most similar profiles are placed adjacent to each other. The length of the 
branches of the dendrograms capturing respectively the tumor samples (top) and the 
genes (left) reflects the similarity of the related elements. Colored dendrogram lines 
indicate pertinent gene clusters. The curves on the right side of the picture represents 
genes discriminating carcinoma from adenoma (red curve) and post-surgical 
recurrences in carcinomas (blue curve).The logarithm (base 10) of p-value of Student T 
test is plotted. The curves were smoothed with a windows of 5. 
B- Extended representation of the list of tumors analyzed in Figure 1A. Each tumor is 
identified by a number, and classified using either a green (adenoma) or a red 
(carcinoma) square and either a black (post-surgical recurrence), a yellow (no 
recurrence)  or a white (not included in the follow-up study) square. 
 
Figure 2: Classification of adrenocortical tumors using specific gene clusters.  
The 57 adrenocortical tumors were reclustered according to the expression patterns of the two 
clusters of genes identified in Figure 1A. The percentage of adenomas or carcinomas present 
within each subgroup resulting from this reclustering is indicated beneath each analysis. The 
abbreviated names of the genes is indicated in front of each row. 
 
Figure 3: Comparative quantitation of IGF2 and HSD3B1 gene expression in 16 
adrenocortical tumors by two distinct methods.  
IGF2 and HSD3B1 mRNA levels were determined in 8 carcinomas and 8 adenomas by cDNA 
arrays (A) or quantitative RT-PCR (B) as described in Material and Methods.  
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Figure 4: Kaplan-Maier recurrence-free survival analysis in 40 patients with 
adrenocortical tumor.  
(A) : overall recurrence-free survival ; (B) : Recurrence-free survival according to the level of 
expression of the IGF2 gene cluster ; (C) : Recurrence-free survival according to the level of 
expression of the Steroidogenesis gene cluster ; (D) : Recurrence-free survival according to the 
combined levels of expression of the steroidogenesis and IGF2 gene clusters. (E) 
Recurrence-free survival according to histological grade (Weiss score). The number of samples 
in each group (n) is indicated over each curve. The probability of significant difference between 
the survival rates of two groups was analyzed using the Wilcoxon test and is indicated in the 
lower right corner of each analysis. It could not be calculated when one group contained no 
recurrence . 
 
Figure 5: Correlation between the steroid secretion profiles and the gene expression 
profiles of adrenocortical tumors. 
Out of the tumor population analyzed in this study, 23 secreted glucocorticoids, 8 were 
non-secreting and 17 had a mixed secretion profile (glucocorticoids and/or mineralocorticoids 
and/or androgens). The picture shows the distribution of these three types of tumors among the 
four groups of gene expression profiles constituted by high or low levels of expression of the 
IGF2 (IGF) and Steroidogenesis (St.) gene clusters. 
 
Figure 6: Identification of a gene cluster that discriminates recurring and non-recurring 
carcinomas.  
(A) Statistical analysis of the expression levels of each individual gene in recurring and 
non-recurring carcinomas (13 samples) allowed to identified this group of 14 genes.  These 
tumors were then reclustered according to the expression pattern of these genes. The data are 
represented as described in Legend to Figure 1. Two distinct subgroups were clearly identified. 
Black squares correspond to tumors that recurred after surgical removal and yellow squares to 
non-recurring tumors. (B) : Kaplan-Maier recurrence-free survival analysis of 13 patients with 
adrenocortical carcinoma and sufficient follow-up according to the separation shown in Figure 
6A. The number of samples in each group (n) is indicated near each curve. The probability of 
significant difference between the survival rates of two groups was analyzed using the 
Wilcoxon test and is indicated in the lower right corner.  
 
 
Clinical characteristics 
Pathological tumor size (cm) (min-max; median) 
Pathological tumor weight (g) (min-max; median) 
Tumor extension (n)  
 localized  
 regional  
 metastatic 
Steroid secretion profile (n)  
 glucocorticoids  
 mineralocorticoids  
 androgens  
 estrogens 
 mixed  
 non-secreting  
 non described 
Follow-up (months) (min-max; median) 
Relapse-free survival (months) (min-max; median) 
Death (n) 
Histological grade (n) 
 adenoma (Weiss criteria < 4) 
carcinoma (Weiss criteria ≥  4) 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Clinical characteristics of the patients 
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46 
2 
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23 
2 
3 
2 
17 
8 
2 
2.1 - 97; 31 
2 - 97; 29 
8 
 
33 
24 
Gene symbol Gene/protein  identity Chromosome 
location 
   
IGF2 Cluster   
IGF2 Insulin-like growth factor-2; somatomedin-A 11p15.5 
FGFR1 Fibroblast growth factor receptor-1 8p11.2-p11.1 
FGFR4 Fibroblast growth factor receptor-4 5q35.1-qter 
TGFB2 Transforming growth factor-ß2 1q41 
TGFBR1 Transforming growth factor-ß receptor type I; activin receptor-like 
kinase 5; ALK5 
9q33-q34 
MST1R Macrophage stimulating protein-1 receptor; Ron protein tyrosine 
kinase 
3p21.3 
KCNQ1OT1 KCNQ1 overlapping transcript 1; lit1 11p15.5 
GAPD Glyceraldehyde 3-phosphate dehydrogenase 12p13.31-p13.1 
   
Steroidogenesis 
Cluster 
  
CYP11A Cytochrome P450 scc; Cholesterol side chain cleavage enzyme 15q24.1 
CYP11B1 Steroid 11ß-hydroxylase; Cytochrome P450 11ß 8q21 
CYP17 Steroid 17α-hydroxylase; Cytochrome P450 17α 10q24.3 
CYP21A2 Cytochrome P450 c21; steroid 21-hydroxylase 6p21.1 
HSD3B1 3ß-hydroxysteroid dehydrogenase/Delta 5 isomerase type 1 1q21.2 
STAR Steroidogenic acute regulatory protein 8p11.2 
INHA Inhibin α subunit  2q33-q36 
CREM cAMP responsive element modulator 10p12.1-p11.2 
RB1 Retinoblastoma protein-1 13q14.1-q14.2 
PPM1A Protein phosphatase 1A, magnesium-dependent;  protein 
phosphatase 2Cα 
11q23.1 
NME1 Non metastatic protein 23 (NM23); Nucleoside diphosphate 
kinase-A  
17q21.3 
S100B S100 calcium binding protein B  21q22.3 
TGFBR3 Transforming growth factor ß receptor III; Betaglycan 1p22.1 
GPC3 glypican 3 Xq26 
   
 
 
 
Table 2 :  Identity of the gene clusters discriminating adenomas from carcinomas 
 
Gene symbol Gene/protein  identity Chromosome 
location 
   
ISGF3G Interferon-stimulated transcription factor 3, gamma 14q11.2 
IL2RG Interleukin 2 receptor, gamma Xq13 
GZMA Granzyme A 5q11-q12 
PTPN2 protein tyrosine phosphatase, non-receptor type 2 18p11.3-p11.2 
ITGB2 Integrin ß2 ; macrophage antigen-1 (mac-1)  21q22.3 
ATF1 Activating transcription factor 1 12q13 
GAPD Glyceraldehyde 3-phosphate dehydrogenase 12p13.31-p13.1 
ACTG1 Actin gamma 1 17q25.3 
TLN1 Talin 1 9p 
PRKCSH Protein kinase C substrate 80K-H 19p13.2-p13.1 
VIL2 Villin 2; ezrin 6q25-q26 
ECE1 Endothelin converting enzyme 1 1p36.1 
CDKN2A Cyclin-dependent kinase inhibitor 2A ; p16 9p21 
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog 14q24.3 
   
 
 
 
Table 3 :  Identity  of the set of genes discriminating recurring from non-recurring carcinomas 






